Home
    • Plans Blog Contact
    Monte Rosa Therapeutics Inc logo

    Monte Rosa Therapeutics Inc

    GLUE
    Last price US$15.51
    Market cap US$1.9b
    12M price change 255.73%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Monte Rosa Therapeutics Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts. Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Monte Rosa Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 06, 2026

    Quarterly result summary

    Revenue was $9M (reported). Operating income was -$15.6M (-84% YoY). Net loss was -$43.4M (from $12.3M).

    Revenue $9M reported
    Operating income -$15.6M -84% YoY
    Net loss -$43.4M from $12.3M
    Cash $626M reported

    What changed

    • Revenue reported to $9M.
    • Operating income -84% YoY to -$15.6M.
    • Net loss was -$43.4M (from $12.3M).

    Guidance / outlook

    we expect to enroll our first patients imminently, positioning us to validate the strong signals of clinical activity we observed in this patient population in our Phase 1/2 trial.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 06, 2026 SEC filing 8-K Aug 06, 2026 SEC filing 8-K May 07, 2026 SEC filing 10-Q May 07, 2026 Earnings release Earnings release May 07, 2026 SEC filing 8-K Mar 17, 2026 Earnings release Earnings release Mar 17, 2026 SEC filing 10-K Mar 17, 2026 SEC filing 10-Q Nov 06, 2025 SEC filing 8-K Nov 06, 2025 Earnings release Earnings release Nov 06, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Monte Rosa Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 1.56/5
    Monte Rosa Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Monte Rosa T... GLUE US$1.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.55/5
    Monte Rosa Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Monte Rosa T... GLUE US$1.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 2.36/5
    Monte Rosa Therapeutics Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Monte Rosa T... GLUE US$1.9b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Monte Rosa Therapeutics Inc logo

    Monte Rosa Therapeutics Inc

    US$15.51

    US$1.9b

    -2.42%

    255.73%